Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01846611
Registration number
NCT01846611
Ethics application status
Date submitted
1/05/2013
Date registered
3/05/2013
Date last updated
1/04/2019
Titles & IDs
Public title
A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Query!
Scientific title
A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Query!
Secondary ID [1]
0
0
ET743OVC3006
Query!
Secondary ID [2]
0
0
CR100983
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Ovarian Neoplasms
0
0
Query!
Peritoneal Neoplasms
0
0
Query!
Fallopian Tube Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Womb (Uterine or endometrial cancer)
Query!
Cancer
0
0
0
0
Query!
Ovarian and primary peritoneal
Query!
Cancer
0
0
0
0
Query!
Stomach
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Trabectedin
Treatment: Drugs - DOXIL
Treatment: Drugs - Dexamethasone
Treatment: Drugs - DOXIL
Experimental: Arm A: trabectedin + DOXIL - Participants will receive DOXIL 30 millgram per meter square (mg/m^2) administered as an intravenous (IV) infusion over approximately 90 minutes followed by trabectedin 1.1 mg/m^2 administered as an IV infusion over approximately 3hours, every 3 weeks. Participants will be pretreated with 20 mg dexamethasone IV (or the IV equivalent) approximately 30 minutes before DOXIL study drug. As of Amendment 6, treatment with trabectedin will be discontinued for participants on treatment with trabectedin and no new participants will receive trabectedin. Participants who, in the opinion of the investigator, are deriving clinical benefit may continue treatment with single-agent DOXIL as per the local standard of care.
Active Comparator: Arm B: DOXIL - Participants will receive DOXIL, 50 mg/m^2 administered as an IV infusion over approximately 90 minutes every 4 weeks.
Treatment: Drugs: Trabectedin
1.1 mg/m^2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle.
Treatment: Drugs: DOXIL
30 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle.
Treatment: Drugs: Dexamethasone
20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion.
Treatment: Drugs: DOXIL
50 mg/m^2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS is defined as the time between the date of randomization and the date of death. Participants who died, regardless of the cause of death, were considered to have had an event.
Query!
Timepoint [1]
0
0
Up to 4.3 years
Query!
Secondary outcome [1]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS is defined as the time between the date of randomization and the date of disease progression or death. PFS was assessed using the response evaluation criteria in solid tumors (RECIST) Version 1.1. As per criteria progressive disease in case of target lesions means at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). Progressive disease in case of non-target lesions means unequivocal progression of existing non-target lesions. In both cases the appearance of one or more new lesions is also considered progression.
Query!
Timepoint [1]
0
0
Up to 4.3 years
Query!
Secondary outcome [2]
0
0
Objective Response Rate (ORR)
Query!
Assessment method [2]
0
0
ORR is defined as the percentage of participants with measurable disease achieving a best overall response of either complete response (CR) or partial response (PR) based on RECIST. CR: disappearance of all target and non-target lesions and normalization of tumor marker levels in non-target lesions. PR: at least a 30 percent (%) decrease in the sum of longest diameter (LD) of target lesions or persistence of one or more non-target lesion(s) or/and maintenance of tumor marker level above the normal limits.
Query!
Timepoint [2]
0
0
Up to 4.3 years
Query!
Eligibility
Key inclusion criteria
- Histologically proven advanced-relapsed epithelial ovarian, primary peritoneal, or
fallopian tube cancer
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
- Received first-line treatment with a platinum-based regimen and had no evidence of
disease progression for >= 6 months after the last dose
- Received second-line treatment with a platinum-based regimen, with progression of
disease after attaining a response
- Progression of disease based on imaging after the second-line platinum-based regimen
(individuals treated with a pegylated liposomal doxorubicin-containing regimen as a
second-line therapy are eligible if subsequent disease progression occurs >=9 months
from the first dose)
- Evidence of measurable disease at screening as evaluated by Response Evaluation
Criteria in Solid Tumors (RECIST) (Version 1.1)
- Participants no longer need to be able to receive intravenous (IV) dexamethasone or an
equivalent IV corticosteroid
- Have a known BRCA 1/2 mutation status (for participants who do not have a known BRCA
1/2 status at screening, a blood sample will be collected to determine the status with
the results available prior to randomization
- Laboratory values within protocol -defined parameters
- Have left ventricular ejection fraction by multigated acquisition scan (MUGA) scan or
2D-ECHO within normal limits for the institution
- Have side effects (except alopecia) of prior treatment resolved to at least Grade 1
according to the National Cancer Institute - Common Terminology Criteria of Adverse
Events (NCICTCAE) (Version 4.0)
- Have a negative urine or serum pregnancy test at screening
- Agrees to protocol-defined use of effective contraception
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Diagnosis of ovarian carcinoma with mucinous histology
- Had more than 2 prior lines of systemic therapy. Maintenance therapies and hormonal
therapies are not considered additional lines of therapy
- Participants who had a prior exposure to trabectedin or hypersensitivity to any of the
excipients will not be excluded from receiving single-agent Doxil
- Prior treatment with doxorubicin or other anthracycline at cumulative doses greater
than 300 mg/m2 (calculated using doxorubicin equivalent doses: 1 mg doxorubicin = 1 mg
Doxil/Caelyx = 1.8 mg epirubicin = 0.3 mg mitoxantrone = 0.25 mg idarubicin)
- Participants unwilling or unable to have a central venous catheter placed will not be
excluded from receiving single-agent Doxil
- Pregnant or breast-feeding
- Would receive study treatment within 3 weeks from radiation therapy, experimental
therapy, hormonal therapy, prior chemotherapy, or biological therapy; use an invasive
investigational device; or is currently enrolled in an investigational study
- History of another invasive malignancy (except non-metastatic basal cell carcinoma or
squamous cell carcinoma of the skin or cervical carcinoma in situ adequately treated)
unless in remission for >=5 years, or a non - invasive malignancy requiring ongoing
therapy
- Known allergies, hypersensitivity, or intolerance to Doxil, dexamethasone, or their
excipients
- Known history of central nervous system metastasis
- Known significant chronic liver disease, such as cirrhosis or active hepatitis
(potential participants who test positive for hepatitis B surface antigen or hepatitis
C antibodies are allowed provided they do not have active disease requiring antiviral
therapy)
- Had a myocardial infarct within 6 months before enrollment, New York Heart Association
(NYHA) Class II or greater heart failure, uncontrolled angina, severe uncontrolled
ventricular arrhythmias, clinically significant pericardial disease, or
electrocardiographic evidence of acute ischemic or active conduction system
abnormalities
- Has any of the following medical conditions: uncontrolled diabetes, psychiatric
disorder (including dementia) that prevents compliance with protocol, uncontrolled
seizures, newly diagnosed deep vein thrombosis, active systemic infection that is
likely to interfere with study procedure or results
- Has any condition that, in the opinion of the investigator, would compromise the
well-being of the participant or the study or prevent the participant from meeting or
performing study requirements
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
16/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
16/11/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
581
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
- Adelaide
Query!
Recruitment hospital [2]
0
0
- Ballarat
Query!
Recruitment hospital [3]
0
0
- Brisbane
Query!
Recruitment hospital [4]
0
0
- Gosford
Query!
Recruitment hospital [5]
0
0
- Parkville
Query!
Recruitment hospital [6]
0
0
- Subiaco
Query!
Recruitment hospital [7]
0
0
- Toorak Gardens
Query!
Recruitment hospital [8]
0
0
- Townsville
Query!
Recruitment hospital [9]
0
0
- Wodonga
Query!
Recruitment hospital [10]
0
0
- Woodville
Query!
Recruitment postcode(s) [1]
0
0
- Adelaide
Query!
Recruitment postcode(s) [2]
0
0
- Ballarat
Query!
Recruitment postcode(s) [3]
0
0
- Brisbane
Query!
Recruitment postcode(s) [4]
0
0
- Gosford
Query!
Recruitment postcode(s) [5]
0
0
- Parkville
Query!
Recruitment postcode(s) [6]
0
0
- Subiaco
Query!
Recruitment postcode(s) [7]
0
0
- Toorak Gardens
Query!
Recruitment postcode(s) [8]
0
0
- Townsville
Query!
Recruitment postcode(s) [9]
0
0
- Wodonga
Query!
Recruitment postcode(s) [10]
0
0
- Woodville
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Illinois
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Indiana
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maine
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New York
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
North Carolina
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oklahoma
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Rhode Island
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
South Carolina
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Tennessee
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Texas
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Utah
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Virginia
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Washington
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Wisconsin
Query!
Country [33]
0
0
China
Query!
State/province [33]
0
0
Guangzhou
Query!
Country [34]
0
0
China
Query!
State/province [34]
0
0
Jinan
Query!
Country [35]
0
0
China
Query!
State/province [35]
0
0
Shanghai
Query!
Country [36]
0
0
China
Query!
State/province [36]
0
0
Shenyang
Query!
Country [37]
0
0
Israel
Query!
State/province [37]
0
0
Beer Sheva
Query!
Country [38]
0
0
Israel
Query!
State/province [38]
0
0
Haifa
Query!
Country [39]
0
0
Israel
Query!
State/province [39]
0
0
Holon
Query!
Country [40]
0
0
Israel
Query!
State/province [40]
0
0
Jerusalem
Query!
Country [41]
0
0
Israel
Query!
State/province [41]
0
0
Kfar Saba
Query!
Country [42]
0
0
Israel
Query!
State/province [42]
0
0
Petah Tikva
Query!
Country [43]
0
0
Israel
Query!
State/province [43]
0
0
Ramat-Gan
Query!
Country [44]
0
0
Israel
Query!
State/province [44]
0
0
Rehovot
Query!
Country [45]
0
0
Israel
Query!
State/province [45]
0
0
Tel Aviv
Query!
Country [46]
0
0
Israel
Query!
State/province [46]
0
0
Zerifin
Query!
Country [47]
0
0
New Zealand
Query!
State/province [47]
0
0
Auckland
Query!
Country [48]
0
0
New Zealand
Query!
State/province [48]
0
0
Wellington
Query!
Country [49]
0
0
Poland
Query!
State/province [49]
0
0
Bydgoszcz
Query!
Country [50]
0
0
Poland
Query!
State/province [50]
0
0
Gdansk
Query!
Country [51]
0
0
Poland
Query!
State/province [51]
0
0
Lublin
Query!
Country [52]
0
0
Poland
Query!
State/province [52]
0
0
Poznan
Query!
Country [53]
0
0
Poland
Query!
State/province [53]
0
0
Warszawa
Query!
Country [54]
0
0
Russian Federation
Query!
State/province [54]
0
0
Arkhangelsk
Query!
Country [55]
0
0
Russian Federation
Query!
State/province [55]
0
0
Chelyabinsk
Query!
Country [56]
0
0
Russian Federation
Query!
State/province [56]
0
0
Ivanovo
Query!
Country [57]
0
0
Russian Federation
Query!
State/province [57]
0
0
Kirov
Query!
Country [58]
0
0
Russian Federation
Query!
State/province [58]
0
0
Krasnodar
Query!
Country [59]
0
0
Russian Federation
Query!
State/province [59]
0
0
Moscow N/a
Query!
Country [60]
0
0
Russian Federation
Query!
State/province [60]
0
0
Moscow
Query!
Country [61]
0
0
Russian Federation
Query!
State/province [61]
0
0
Nalchik
Query!
Country [62]
0
0
Russian Federation
Query!
State/province [62]
0
0
Nizhniy Novgorod
Query!
Country [63]
0
0
Russian Federation
Query!
State/province [63]
0
0
Nizhny Novgorod
Query!
Country [64]
0
0
Russian Federation
Query!
State/province [64]
0
0
Omsk
Query!
Country [65]
0
0
Russian Federation
Query!
State/province [65]
0
0
Orenburg
Query!
Country [66]
0
0
Russian Federation
Query!
State/province [66]
0
0
Pyatigorsk
Query!
Country [67]
0
0
Russian Federation
Query!
State/province [67]
0
0
Ryazan
Query!
Country [68]
0
0
Russian Federation
Query!
State/province [68]
0
0
Saint Petersburg
Query!
Country [69]
0
0
Russian Federation
Query!
State/province [69]
0
0
Saint-Petersburg,
Query!
Country [70]
0
0
Russian Federation
Query!
State/province [70]
0
0
Sochi
Query!
Country [71]
0
0
Russian Federation
Query!
State/province [71]
0
0
St Petersburg
Query!
Country [72]
0
0
Russian Federation
Query!
State/province [72]
0
0
Ufa
Query!
Country [73]
0
0
Russian Federation
Query!
State/province [73]
0
0
Yaroslavl
Query!
Country [74]
0
0
South Africa
Query!
State/province [74]
0
0
Amanzimtoti
Query!
Country [75]
0
0
South Africa
Query!
State/province [75]
0
0
Cape Town
Query!
Country [76]
0
0
South Africa
Query!
State/province [76]
0
0
Durban
Query!
Country [77]
0
0
South Africa
Query!
State/province [77]
0
0
Johannesburg
Query!
Country [78]
0
0
South Africa
Query!
State/province [78]
0
0
Port Elizabeth
Query!
Country [79]
0
0
South Africa
Query!
State/province [79]
0
0
Pretoria
Query!
Country [80]
0
0
Switzerland
Query!
State/province [80]
0
0
Bern
Query!
Country [81]
0
0
Switzerland
Query!
State/province [81]
0
0
Zurich
Query!
Country [82]
0
0
United Kingdom
Query!
State/province [82]
0
0
Bebington
Query!
Country [83]
0
0
United Kingdom
Query!
State/province [83]
0
0
Glasgow
Query!
Country [84]
0
0
United Kingdom
Query!
State/province [84]
0
0
Guilford
Query!
Country [85]
0
0
United Kingdom
Query!
State/province [85]
0
0
London
Query!
Country [86]
0
0
United Kingdom
Query!
State/province [86]
0
0
Maidstone
Query!
Country [87]
0
0
United Kingdom
Query!
State/province [87]
0
0
Manchester
Query!
Country [88]
0
0
United Kingdom
Query!
State/province [88]
0
0
Plymouth
Query!
Country [89]
0
0
United Kingdom
Query!
State/province [89]
0
0
Swansea
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Janssen Research & Development, LLC
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
PharmaMar
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of trabectedin+DOXIL as a
third-line chemotherapy regimen (treatment) in patients with platinum-sensitive
advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer who
received 2 previous lines of platinum-based chemotherapy.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01846611
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Janssen Research & Development, LLC Clinical Trial
Query!
Address
0
0
Janssen Research & Development, LLC
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01846611
Download to PDF